CVSI - CV Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.2600
+0.1700 (+15.60%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.0900
Open1.0900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.0500 - 1.2800
52 Week Range0.8200 - 6.5900
Volume2,072,244
Avg. Volume951,853
Market Cap125.114M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    CV Sciences, Inc. to Participate at the 22nd Annual ICR Conference

    SAN DIEGO, Jan. 08, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD).

  • GlobeNewswire

    Tim Hitchman, PhD, Joins CV Sciences, Inc. as Director of Operations

    Hitchman Brings Deep Experience in Product Development, Commercialization and Operations SAN DIEGO, Dec. 17, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV.

  • Business Wire

    CV SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CV Sciences, Inc. - CVSI

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into CV Sciences, Inc. (OTC: CVSI).

  • GlobeNewswire

    CV Sciences to Present at the 12th Annual LD Micro Main Event

    SAN DIEGO, Dec. 03, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD).

  • GlobeNewswire

    CV Sciences, Inc. Announces New Distribution Partnership With Southeastern Grocers

    New Partnership with Southeastern Grocers Launches PlusCBD™ Oil Topical Products and Dietary Supplements at 115 Winn-Dixie Stores in Florida and 37 BI-LO Stores in South.

  • GlobeNewswire

    CV Sciences, Inc. Reports Third Quarter 2019 Financial Results

    Increased Retail Distribution by Over 800 Stores SAN DIEGO, Nov. 05, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent.

  • GlobeNewswire

    CV Sciences, Inc. Applauds USDA’s Establishment of the U.S. Domestic Hemp Production Program

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce its support of the U.S. Department of Agriculture’s (USDA) progress on implementation of the hemp provisions of the 2018 Farm Bill. On October 29, 2019, U.S. Secretary of Agriculture Sonny Perdue announced the interim final rule for the U.S. Domestic Hemp Production Program.

  • GlobeNewswire

    CV Sciences, Inc. Appoints Beth Altman to its Board of Directors

    SAN DIEGO, Oct. 29, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD).

  • GlobeNewswire

    CV Sciences, Inc. to Sponsor 26th Annual HIACON Conference in Charlotte, North Carolina on Nov. 1-4, 2019

    This year’s conference will be held November 1st through November 4th in Charlotte, North Carolina, and marks a significant milestone for HIACON as the longest-standing hemp conference in its 26th year. “We are looking forward to joining HIACON as the title sponsor for our 4th consecutive year,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. to Announce Third Quarter 2019 Results on November 5, 2019

    SAN DIEGO, Oct. 23, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD).

  • GlobeNewswire

    CV Sciences, Inc. Appoints Dr. Paul Blake to its Board of Directors

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Dr. Paul Blake to its Board of Directors effective October 21, 2019. “We are very pleased to have Dr. Blake join our Board of Directors,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. Announces Expanded Distribution Partnership With The Vitamin Shoppe

    Partnership Broadens Distribution of PlusCBD™ Oil Products to More Than 500 The Vitamin Shoppe Locations SAN DIEGO, Oct. 17, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the.

  • GlobeNewswire

    CV Sciences, Inc. Announces Distribution Partnership With Harris Teeter

    Partnership Broadens Distribution of PlusCBD™ Oil Products to 150 Harris Teeter Locations SAN DIEGO, Oct. 01, 2019 --  CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV.

  • GlobeNewswire

    CV Sciences Applauds House Passage of the SAFE Banking Act of 2019

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announces its full support of the House of Representatives’ passage of the Secure and Fair Enforcement (SAFE) Banking Act, a key measure that would enable banks to serve cannabis-related businesses in legal medical and adult-use U.S. states. The SAFE Banking Act passed the House on Wednesday, September 25th by a vote of 321 to 103, becoming the first standalone marijuana reform bill to ever clear a chamber of Congress. “This is a significant step for the evolution and advancement of the legal cannabis industry,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. Launches Seven New Body Care Hemp CBD Products at Natural Products Expo East

    SAN DIEGO, Sept. 24, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol.

  • GlobeNewswire

    CV Sciences, Inc. Announces Plans to File Request For Continued Examination of Its US Patent Application

    SAN DIEGO, Sept. 19, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol.

  • GlobeNewswire

    CV Sciences, Inc. Wins 2019 NEXTY Award

    Company’s industry-dominating hemp extract brand, PlusCBD Oil™, wins Consumer Choice Award at Natural Products Expo East SAN DIEGO, Sept. 17, 2019 -- CV Sciences, Inc..

  • GlobeNewswire

    Pro Mountain Biker Cam McCaul Partners with PlusCBD™ Oil

    CV Sciences, Inc. (CVSI) (the “Company,” “CV Sciences,” “our” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce they have partnered with professional mountain biker Cam McCaul to endorse industry-dominating PlusCBD™ Oil brand. McCaul, one of the leading riders on the freeride mountain biking scene for the past two decades, has won major global freeride events, including Crankworx Colorado, the Bearclaw Invitational, District Ride, and the Claymore Challenge. McCaul was an early leader in the sport of mountain bike slopestyle and has helped innovate both the sport and the riding style.

  • GlobeNewswire

    CV Sciences, Inc. to Present and Sponsor Natural Products Expo East

    Company enters its 5th year exhibiting at the nation's largest natural products trade show, offering natural health retailers show specials, one-on-one education, and a wide.

  • GlobeNewswire

    CV Sciences, Inc Appoints Terri Funk Graham to Board of Directors

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that Terri Funk Graham has been appointed to CV Sciences’ Board of Directors effective August 22, 2019. “Terri brings extensive Fortune 1000 experience serving on Boards of Directors and in senior leadership roles – we are thrilled to welcome her to our Board of Directors,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. Announces Distribution Partnership With The Vitamin Shoppe

    Partnership Broadens Distribution of PlusCBD™ Oil Products to More Than 380 Vitamin Shoppe Locations SAN DIEGO, Aug. 22, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”,.

  • GlobeNewswire

    CV Sciences, Inc. CEO Issues Letter to Shareholders

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its industry-dominating brand, PlusCBD™ Oil, today released a letter to shareholders from CEO Joseph Dowling. Last week we issued our second quarter results, reporting the highest quarterly revenue in our company’s history, continuing a streak of 14 consecutive quarters of sequential revenue growth. This consistent growth is a reflection of the strength of the PlusCBD™ Oil brand and our growing distribution across retail channels.

  • GlobeNewswire

    CV Sciences, Inc. Reports Second Quarter 2019 Financial Results

    Record quarterly revenue Increased retail distribution by over 1,200 stores SAN DIEGO, Aug. 06, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) ("CV Sciences" or the “Company”).

  • GlobeNewswire

    CV Sciences, Inc. Announces Expanded Distribution Partnership With The Kroger Co.

    PlusCBD™ Oil Topicals Now Available at 1,350 Kroger Stores SAN DIEGO, July 30, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a.

  • GlobeNewswire

    CV Sciences, Inc. Applauds Ohio’s State Law Passage of Senate Bill 57

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its industry-dominating brand, PlusCBD™ Oil, announces its full support of Ohio’s state law passage of Senate Bill 57 (SB 57), which makes hemp and hemp CBD products legal in Ohio. SB 57 was approved by the Ohio House Agriculture and Rural Development Committee in June and passed the House floor on an 88-3 vote on July 17th.